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Abstract
Background: Autophagy-mediated self-digestion of cytoplasmic inclusions may be protective against
neurodegenerative diseases such as Parkinson’s disease (PD). However, excessive autophagic activation evokes
autophagic programmed cell death.
Methods: In this study, we aimed at exploring the role of autophagy in the pathogenesis of rotenone-induced
cellular and animal models for PD.
Results: Reactive oxygen species over-generation, mitochondrial membrane potential reduction or apoptosis rate
elevation occurred in a dose-dependent fashion in rotenone-treated human neuroblastoma cell line SH-SY5Y. The
time- and dose-dependent increases in autophagic marker microtubule-associated protein1 light chain 3 (LC3)
expression and decreases in autophagic adaptor protein P62 were observed in this cellular model. LC3-positive
autophagic vacuoles were colocalized with alpha-synuclein-overexpressed aggregations. Moreover, the number of
autophagic vacuoles was increased in rotenone-based PD models in vitro and in vivo.
Conclusions: These data, along with our previous finding showing rotenone-induced toxicity was prevented by the
autophagy enhancers and was aggravated by the autophagy inhibitors in SH-SY5Y, suggest that autophagy
contributes to the pathogenesis of PD, attenuates the rotenone toxicity and possibly represents a new subcellular
target for treating PD.
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Background
Parkinson’s Disease (PD) is the second most common neu-
rodegenerative disease and affects as many as 1–2%o ft h e
worldwide population aging at 60 years and older [1]. The
pathological hallmarks of PD include the loss of dopamin-
ergic (DA) neurons in the substantia nigra pars compacta
(SNc) and DA terminals in the striatum, and the presence
of proteinaceous cytoplasmic inclusions called Lewy bod-
ies. Currently, the precise pathogenic mechanisms in PD
remain incompletely understood. As Lewy Bodies contain
aggregated alpha-synuclein, ubiquitin and other misfolded
proteins [1], a growing attention has been drawn to the
role of autophagy in the pathogenesis of PD [2]. Different
from ubiquitin-proteasome system which degrades
proteins through the narrow barrel of proteasome,
macroautophagy (referred to below as autophagy) is
responsible for the largely non-specific bulk degrad-
ation of long-lived cytosolic proteins and organelles.
It is acknowledged that autophagy is related to PD.
Autophagosomes containing neuromelanin and lipofuscin
have been identified in degenerating neurons in brains
with PD [3]. Moreover, overexpressions of alpha-synuclein
mutants have been reported to activate autophagy [4-6].
Rapamycin (Rap), known as an autophagy inducer, is
neuroprotective in parkinsonian cellular and mice models,
by enhancing autophagy to degrade misfolded proteins
[7]. Our previous findings suggested that valproic acid and
carbamazepine (the most commonly used anti-epilepsy
and mood-stabilizing medications with low-risk and easy
administration), as well as Rap and lithium, might be po-
tential therapeutics for PD as autophagy enhancers [8].
* Correspondence: wangtaowh@yahoo.cn
†Equal contributors
1Department of Neurology, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan,
Hubei 430022, China
Full list of author information is available at the end of the article
© 2013 Xiong et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Xiong et al. Behavioral and Brain Functions 2013, 9:13
http://www.behavioralandbrainfunctions.com/content/9/1/13On the other hand, 3-methyladenine, an autophagy in-
hibitor, has reportedly offered neuroprotection against
6-hydroxydopamine toxicity [9], suggesting that exces-
sive activation of autophagy during neuronal loss par-
ticipates in the pathogenesis pathway of PD [10]. That
is to say, both autophagy inducer and inhibitor have
been proven to serve as neuroprotectors against PD.
There are still many controversial and unsolved prob-
lems regarding the role of autophagy in PD. First,
whether it is autophagy activation or autophagy sup-
pression that confers neuroprotection against PD; sec-
ond, whether autophagy is a defense mechanism or a
response to the DA neuron death; third, whether au-
tophagy is a key mechanism or just an innocent by-
stander in the pathogenesis of PD [11,12]. Therefore,
we need to better understand the role of autophagy in
the pathogenesis of PD prior to any clinical application
of autophagy-based medications in PD subjects.
Rotenone, a potent mitochondrial complex I inhibitor,
is one of the most relevant neurotoxins to induce par-
kinsonian symptoms [6,13-15]. Despite debates, the rote-
none model is able to recapitulate slow and specific loss
of DA neurons and over-expression of alpha-synuclein
and better mimics the clinical features of idiopathic PD
[16-20]. Among the various models for PD, the rotenone
model has recently drawn particular attention for two
reasons: 1) it reproduces most of the motor symptoms
and the histopathological features of PD, including Lewy
bodies [21,22]; and 2) rotenone and other pesticides are
powerful inhibitors of mitochondrial respiration and as-
sociated with the higher incidence of sporadic Parkin-
sonism among the population of rural areas [23-26].
Thus, rotenone-induced parkinsonian models were
chosen to explore the role of autophagy in PD in this
study. We found that rotenone induced time- and dose-
dependent apoptosis of SH-SY5Y cells increases the au-
tophagic marker microtubule-associated protein1 light
chain 3 expression, and increases the number of autoph-
agic vacuoles, and decreases the autophagic adaptor pro-
tein P62 expression. These data indicated that autophagy
was involved in the pathogenesis of rotenone-induced
PD models, revealing a neuroprotective alternative to
treating PD.
Methods
Cell culture
SH-SY5Y cells (American type culture collection, gift
from Dr. Jianguo Chen) were cultured in DMEM/F12
medium (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (Invitrogen) at 37°C with
5% CO2 and 95% air (vol/vol). Rotenone (Sigma-Aldrich,
St. louis, MO, USA) was dissolved in dimethyl sulfoxide
before dilution with the culture medium. The final con-
centration of dimethyl sulfoxide (DMSO) per well was
0.2%. DMSO alone was added to the culture medium in
control group (“Con-group”). For the dose-dependent
study, rotenone was given at a concentration of 0.1, 0.5,
1, 2.5, 5, 10 and 20 μM for 24 hours. For the time-
dependent study, rotenone (2.5μM) was given for 3, 6,
12, 24, 36 or 48 hours to induce cell damage.
MTT assay
Cell viability was assessed by the 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) method
[27,28]. The MTT assay is a colorimetric assay of the ac-
tivity of cellular enzymes that reduce the tetrazolium
dye, MTT, into insoluble formazan, giving a purple color.
Briefly, SH-SY5Y cells were plated at a density of 1 × 10
4
cells per well in 96-well plates. After exposure to rotenone
and vehicle, 20 μl of MTT (5 mg/ml, Sigma-Aldrich) was
added into each well before incubation in a humidified in-
cubator at 37°C for 4 hours to allow the formation of pur-
ple formazan crystal. Then, 100 μlo ft h es o l u b i l i z a t i o n
reagent (0.1 N HCl in anhydrous isopropanol, Sigma-
Aldrich) was added into each well and lysate spectro-
photometrically measured for absorption at λ 570 nm
with background subtraction at 690 nm. Cell viability
was expressed as a percentage of the value in untreated
control cells.
Detection of apoptosis, mitochondrial membrane
potential (MMP) and reactive oxygen species (ROS) in
SH-SY5Y cells
Annexin V was used to probe phosphatidylserine expres-
sion on the cell surface, an event found in apoptosis as
well as other forms of cell death [29]. In this study,
staurosporine (50nM, Sigma-Aldrich) treatment for 24
hours was employed as a positive control to induce cell
apoptosis. SH-SY5Y cells were harvested after treatment
with 0.25% trypsin, washed with phosphate buffered so-
lution (PBS) and incubated in PBS containing the
Annexin V-fluorescein isothiocyanate (Annexin V, 5 μl
in 100 μl PBS) and Propidium Iodide (PI, 100 μg/ml
working solution, 1 μl in 100 μl) at 37°C in darkness for
15 minutes. The apoptosis rate = [Annexin V(+)PI(−)
cells + Annexin V(+)PI(+) cells] /total cell × 100%. The
specific fluorescence of 10,000 cells was analyzed on
FACScalibur (BD Biosciences, Franklin Lakes, NJ, USA)
within 1 hour after antigen antibody reaction [27-29].
Data were analyzed by using FSC express version 3.0
(De Novo Software, Los Angeles, CA, USA).
It was reported that a decrease in MMP was one of
the earliest events in apoptosis [30]. When stained with
JC-1, red fluorescence of mitochondria was due to the
formation of J-aggregates at high MMP, and green fluor-
escence of mitochondria to the formation of JC-1 mono-
mers at low MMP [31]. ROS detection was based on
ROS-catalyzed formation of fluorescent compound DCF.
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sively through the cellular membrane. With intracellular
esterase activity, DCFH-DA formed a nonfluorescent
compound DCFH, which was oxidized into the fluores-
cent compound DCF by ROS [32]. For the analysis of
MMP and ROS, cells were harvested, resuspended in
PBS and immediately stained with JC-1 (1 mg/ml in
DMSO, Molecular Probes, Eugene, OR, USA) [31] or
DCFH-DA (10 μM, Invitrogen) [32], and incubated at
37°C for 30 minutes in the darkness. After washing with
ice-cold PBS twice, the samples were subject to
FACScan flow Cytometry. Data were analyzed again by
using FSC express version 3.0 (De Novo Software).
Immunoblotting
The microtubule-associated protein1 light chain 3 (LC3)
was a marker for all types of autophagic vacuolar organ-
elles. A higher LC3 expression level meant more autoph-
agic vacuolar organelles in the cells. It was reported that
LC3 expression level could be related to the induction of
autophagy or a block of autophagy and subsequent accu-
mulation of LC3 [33-35]. The mammalian proteins p62
and NBR1 were selectively degraded by autophagy and
could act as cargo receptors or adaptors for the autopha-
gic degradation of ubiquitinated substrates [36,37]. The
conversion of LC3-I into LC3-II (LC3-II level compared
to LC3-I level) and the expression of P62 (which was de-
graded by autophagy) were indicative of autophagic ac-
tivity. Higher ratio of LC3-II/LC3-I and lower p62
expression means higher autophagic activity. In this
study, LC3 and p62 levels were measured by an im-
munoblotting method [27,28,38]. Cells were rinsed twice
with cold PBS and lysed in buffer (50 mM Tris–HCl, pH
7.5, 100 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS,1 mM EDTA, 1 mM sodium orthovanadate,10
mM sodium fluoride, and 100 mg/ml PMSF). After incu-
bation on ice for 30 minutes, cell lysates were then clari-
fied by centrifugation at 12,000 × g and 4°C for 10 minutes
and the supernatant saved for protein analysis and Western
blotting. Total protein concentration was determined by
the BCA kit (Sigma-Aldrich). Equal amounts of proteins
(30 μg) were fractionated by 15% SDS-PAGE, and trans-
ferred to nitrocellulose membrane. The membrane was
blocked with 5% non-fat milk in Tris-buffered saline (TBS)
for 1 hour at room temperature, followed by incubation
with primary antibodies against LC3, P62 (Sigma-Aldrich,
St. Louis, MO, USA) and β-actin (Santa Cruz, Santa Cruz,
CA, USA) overnight at 4°C. The membranes were then
washed twice with TBS tween-20 and probed with the cor-
responding secondary antibodies conjugated with HRP
at room temperature for 1 hour. Detection was car-
ried out using an enhanced chemiluminescence detection
kit (Pierce, Rockford, IL, USA), followed by autoradiog-
raphy. The relative intensity of bands was quantified using
Quantity One analysis system (Quantity One, Hercules,
CA, USA). All data from three independent experiments
were expressed as the ratio to optical density values of the
corresponding controls for statistical analyses.
Immunostaining
SH-SY5Y cells grown on cover slips were fixed with 4%
paraformaldehyde at 4°C for 30 minutes, washed with PBS
and permeabilized with 0.1% Triton-X100 and 5% bovine
serum albumin (Invitrogen) in PBS [38], followed by incu-
bation at 4°C overnight with the LC3 antibody (1:100,
rabbit polyclonal antibody, Sigma-Aldrich, St. Louis, MO,
USA) without or with alpha-synuclein (SNCA) antibody
(1:100, mouse monoclonal antibody, Billerica, MA, USA).
The corresponding secondary FITC-conjugated donkey-
anti-rabbit IgG (1:200, vol/vol, Proteintech, Chicago, IL,
USA) without or with Cy3-conjugated goat-anti-mouse
IgG (1:500, vol/vol, Proteintech, Chicago, IL, USA) diluted
in 10 μg/ml Hoechst 33258 (Sigma-Aldrich) was applied
at room temperature for 1 hour. Cells were observed by
using a confocal microscope (Olympas, Tokyo, Japan) and
the images (50 per group, repeat for 3 times) were ana-
l y z e db yad e s i g n - b a s e du n b i a s e dm e t h o da n da
morphometry/image analysis system (Image-Pro Plus
6.0 software package, Bethesda, MD, USA; Edit-
Convert to-Gray Scale- Enhance-Invert contrast-Apply
contrast –Measure-Count/Size-Measure-Density Mean).
Rotenone-induced hemiparkinsonian rat model
This study was approved by the Ethical Committee on
Animal Experimentation of Tongji Medical College,
Huazhong University of Science and Technology, China.
The rotenone-induced stereotaxical hemiparkinsonian
rat (inbred adult female Sprague–Dawley rats, 220–260
g) model was used in this study [6]. Briefly, animals were
anesthetized with chloral hydrate (400 mg/kg in 0.9%
NaCl, i.p.) and fastened on a cotton bed over a stereo-
taxic frame (RWD Life Science, Shenzhen, China). Rote-
none dissolved in DMSO (3 μg/μl) was infused into the
right ventral tegmental area (AP: 5.0 mm; L: 1.0 mm;
DV: 7.8 mm) at a flow rate of 0.2 μl/minute. The needle
was left in place for additional 5 minutes for complete
diffusion of the drug. Rotenone was infused into the
right SNc (AP: 5.0 mm; L: 2.0 mm; DV: 8.0 mm) at a
flow rate of 0.2 μl/minute, with a 5-minute needle reten-
tion. After needle withdrawal, proper postoperative care
was given until the animals recovered completely. The
animals were administrated with ibuprofen and penicil-
lin in the drinking water for 24 hours to alleviate poten-
tial postsurgical discomfort and to prevent infection.
Ultrastructural study
The preparation for electron microscopy (EM) was de-
scribed previously [6]. Harvested by detaching with
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http://www.behavioralandbrainfunctions.com/content/9/1/13Figure 1 Rotenone dose- and time-dependently induced cytotoxicity in SH-SY5Y. The MTT assay was employed to assess the cell viability
after rotenone administration. For dose-dependence, rotenone was given at a concentration of 0.1, 0.5, 1, 2.5, 5, 10 and 20 μM for 24 hours. For
time-dependence, rotenone (2.5μM) was given for 3, 6, 12, 24, 36 and 48 hours respectively to induce cell damage. (A) Dose-dependent effect of
24-hour treatment with rotenone on cell proliferation in SH-SY5Y (relative MTT value); (B) Time-dependent effect of rotenone (2.5 μM) on
SH-SY5Y viability with different experimental time points (from 1–48 hours after rotenone administration; *P < 0.05, compared to Con-group).
Figure 2 Rotenone evoked apoptosis, MMP reduction and ROS generation dose- and time-dependently in SH-SY5Y. For Annexin V/PI
double-staining, the apoptosis rate was a sum of both early and late apoptosis rates (apoptosis rate = [Annexin V(+)PI(−) cells + Annexin V(+)PI(+)
cells] /total cell × 100%), staurosporine (STS, 50nM, Sigma-Aldrich) treatment for 24 hours was used as a positive control to induce cell apoptosis.
The apoptosis rate of Con-, Rot-0.1μM, Rot-0.5μM, Rot-1μM, Rot-2.5μM, Rot-5μM, Rot-10μM, Rot-20μM and STS-group was 2.60±0.90%, 3.00±0.60%,
4.30±1.20%, 4.80±1.80%, 6.50±0.98%, 7.20±2.10%, 13.00±3.00%, 19.00±2.70% and 42.31±7.90%, respectively. The JC-1 staining was used to assess
the MMP of SH-SY5Y cells, the percentages of JC-1 monomers presented the percentages of SH-SY5Y cells with low MMP. The relative intensity of
DCF was employed to evaluate the ROS level in SH-SY5Y cells. (A), (D): Statistical analysis of apoptosis rates in different groups. (B), (E): Relative
percentage of JC-1 monomers-positive cells (cells with low MMP) in different groups. (C), (F): Fluorescence intensity of DCFH in all groups.
(*P < 0.05, compared to Con-group).
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then fixed in 0.01 M PBS containing 2.5% glutaralde-
hyde. For the brain tissues, the animals were sacrificed 1
day, 2 days, 1 week, 2 weeks or 4 weeks after the stereo-
logical surgery. A 1-mm
3 tissue block from the left and
right SNc regions (−4.5 to −6.2 mm caudal to the
bregma) was micro-punched, fixed in PBS containing
2.5% glutaraldehyde, and preserved at 4°C for further
processing. The fragments were post-fixed in 1% os-
mium tetroxide in the same buffer, dehydrated in graded
alcohols, embedded in Epon 812, sectioned with an ul-
tramicrotome, and stained with uranyl acetate and lead
citrate. The sections were examined with a transmission
electron microscope (TEM; Technai 10, Philips, the
Netherlands). For the SH-SY5Y cell-based study, the ul-
trastructural images were quantified by randomly
counting of 100 cells and assessing the percentage of the
cells with one or more autophagic vacuoles [39]. For the
animals study, three blocks of SNc from each group
were sectioned discontinuously for 5 slices, and 50 cell
profiles (with a nucleus) were examined on each grid for
counting the autophagic vacuoles per cell profile at X
13,500 magnification [40,41]. Each experiment was
conducted in triplicate.
Statistical analyses
Statistical analysis was carried out by using SPSS version
12.0 for Windows software (SPSS, Chicago, IL, USA).
Given a normal distribution in all groups, intergroup
differences were assessed by one-way analysis of variance
(ANOVA) followed by Least square difference's post hoc
test [42]. Results are presented as mean ± SEM, with
P value of < 0.05 as statistically significant.
Results
Rotenone affected SH-SY5Y cell proliferation time- and
dose-dependently
We first assessed the effects of different concentrations
of rotenone on the proliferation of SH-SY5Y cells based
on the MTT test. Compared with Con-group, rotenone
administration for 24 hours caused a significant decrease
in cell proliferation in 0.5, 1, 2.5, 10, 20, 40 and 80 μM
group, respectively (Figure 1A). For the time-dependence
study, rotenone (2.5μM) significantly decreased the rela-
tive MTT value by 19.01%, 30.88%, 45.04%, 51.86%,
73.40% and 81.1% in Rot-3h, Rot-6h, Rot-12h, Rot-24h,
Rot-36h , Rot-48h and Rot-72h group compared with the
Con-group (Figure 1B).
Rotenone induced dose- and time-dependent apoptosis,
MMP reduction and ROS generation in cultured SH-SY5Y
cells
It is unclear whether the decreased MTT value was at-
tributable to rotenone-based inhibition of cell prolifera-
tion or rotenone-induced increases of SH-SY5Y
apoptosis. To clarify the effects of rotenone on SH-SY5Y
cells, we further performed the apoptosis assessment by
Annexin V/PI double-staining and JC-1 staining. In
Figure 3 Rotenone activated autophagy in SH-SY5Y. LC3/P62 immunoblotting was used to track the conversion of LC3-I into LC3-II and the
expression of P62 for autophagic activity. (A) The immunoblotting of LC3-II/LC3-I, P62 and β-actin from Con-, Rot-0.5μM, Rot-1μM, Rot-2.5μM, Rot-5μM
and Rot-10μM groups; (C), (D) Quantitative analysis of immunoblotting of LC3-II/LC3-I and P62 both controlled by β-actin, respectively. (B)T h e
immunoblotting of LC3- II/I, P62 and β-actin in a Rot (2.5μM) time-dependent manner from Con-, Rot-3h, Rot-6h, Rot-12h, Rot-24h, Rot-36h
and Rot-48h groups; (E), (F) Quantitative analysis of immunoblotting of LC3-II/LC3-I, P62 controlled by β-actin (*P < 0.05, compared to Con-group).
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SY5Y cells were double-stained with FITC-conjugated
Annexin V and PI. The dose-dependent data indicated
that rotenone treatment evoked concentration-dependent
apoptosis in SH-SY5Ycells. The apoptosis rate of the Rot-
2.5 μM , Rot-5μM, Rot-10μM, Rot-20μM or staurosporine
group was statistically significantly different from that in
Con-group (Figure 2A). As the amount of the shift
from J-aggregates to JC-1 monomer, 4.02±1.62%, 5.79±
2.04%, 5.43±1.86%, 6.12±1.45%, 7.48±1.20%, 15.02±
1.95%, 21.94±3.83% and 25.84±4.15% of SH-SY5Y cells
formatted JC-1 monomers in Con-, Rot-0.1μM, Rot-0.5μM,
Rot-1μM, Rot-2.5μM, Rot-5μM, Rot-10μM and Rot-20μM
group, respectively (Figure 2B). Rotenone infusion caused
ROS generation in Rot-0.1μM, Rot-0.5μM, Rot-1μM,
Rot-2.5μM, Rot-5μM, Rot-10μMo rR o t - 2 0 μMg r o u pc o m -
pared with Con-group (Figure 2C). The ROS generation in
the Rot-2.5μM, Rot-5μM, Rot-10μMo rR o t - 2 0 μM
group was significantly different from that in the Con-
group. Rotenone (2.5 μM) conspicuously evoked the
apoptosis (Figure 2D) and MMP reduction (Figure 2E)
of SH-SY5Y cells in a time-dependent fashion as well.
After 12 hours treatment with 2.5 μM rotenone, SH-
SY5Y cells began to show apoptotic changes and MMP
reduction. Moreover, 3-hour treatment with rotenone
(2.5 μM) caused time-dependently significant ROS
generation and the ROS reached the crest value from
the 12-hour to 72 hour time points in SH-SY5Y cells
(Figure 2F).
Rotenone up-regulated LC3 expression and down-
regulated P62 expression in SH-SY5Y at an early stage
after administration
The Western blotting study showed that the ratio of
LC3-II to LC3- I in Rot-2.5μM, Rot-5μM or Rot-10μM
group was 80.20%, 212.48% or 108.55% higher than that
in Con-group. There was no significant difference be-
tween Rot-0.5μM orRot-1μM and Con-groups (Figure
3A, C). The expression of P62 in Rot-2.5μM, Rot-5μM
and Rot-10μM group was significant lower than the
Con-group. The P62 expression in Rot-1μM, Rot-2.5μM,
Rot-5μM or Rot-10μM was obviously different from that
in the Con-group (Figure 3A, D). To confirm the LC3
expression and to observe the LC3 distribution in cells,
the LC3 immunostaining was employed. The relative
mean fluorescence intensity of LC3 was significant
higher in the Rot-2.5μM compared to that in the Con-
group (Figure 4A,B and E). LC3/SNCA double-
immunostaining showed that SNCA-overexpressed ag-
gregations were colocalized with LC3-positive autophagic
vacuoles (Figure 4C, D), demonstrating that autophagy
was involved in abnormal protein degradation in the
rotenone-induced cell model of PD.
Data from the time-dependence study indicated the ra-
tio of LC3-II to LC3- I in Rot-12h, Rot-24h, Rot-36h and
Rot-48h group was significant higher than that in Con-
group. There was no significant difference between Rot-
3h, Rot-6h and Con-groups (Figure 3B, E). The expres-
sion of P62 in Rot-3h, Rot-12h, Rot-24h, Rot-36h and
Rot-48h group was 23.48%, 58.82%, 90.02%, 68.32% and
93.02% lower than control group (Figure 3B, F). These
data indicated the activation of autophagy pathway in
SH-SY5Y cells at the early stage after rotenone infusion
(within 24 hours after rotenone treatment).
Rotenone induced autophagic vacuole formation in SH-
SY5Y cells and SNc neurons
The ultrastructural manifestation represents a “gold
standard” method to identify autophagic vacuoles [43].
Observed through a TEM, SH-SY5Y had a high nucleo-
cytoplasmic ratio and a large nucleus, an irregular
Figure 4 LC3 immunostaining in rotenone-treated SH-SY5Y.
Immunostaining was performed to assess the LC3/SNCA expression
and distribution in SH-SY5Y cells treated with or without rotenone
(2.5μM for 24 hours). The nuclei were stained by Hoechst33258.
(A, B) LC3 immunofluorescence staining for Con- and Rot-2.5μM
group; (C, D) LC3/SNCA double immunostaining for Con- and Rot-2
.5μM group; (E) statistical analysis of relative mean fluorescence
intensity of LC3 immunofluorescence staining (Scale bar = 20 μm;
*P < 0.05, compared to Con-group).
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there were no autophagic vacuoles except normal mito-
chondria, rough endoplasmic reticulum, and ribosomes
which were observed in SH-SY5Y cells (Figure 5B). In
the presence of rotenone, there was time-dependent for-
mation of autophagic vacuoles, mitochondrial swelling,
mitochondrial crest fracture and mitochondrial vacuolar
degeneration within 24-hour administration (Figure 5C-I).
Interestingly, an increase in mitochondrial numbers could
be observed.
Our previous study developed a rotenone (the mito-
chondrial complex-I inhibitor) model by stereotaxical in-
fusion with small doses of rotenone into two brain sites:
the right ventral tegmental area and the substantia nigra.
Figure 5 Rotenone-induced ultrastructural changes in SH-SY5Y. The ultrastructural changes in different rotenone-treated groups.
A: high nucleo-cytoplasmic ratio and large nucleolus of SH-SY5Y cells of Con-group; B: normal mitochondria, rough endoplasmic reticulum and
ribosomes (Con-group); C: mitochondria, rough endoplasmic reticulum, ribosomes and autophagic vacuoles (Arrow, Rot-1h group); D:
mitochondria, rough endoplasmic reticulum, ribosomes and autophagic vacuoles (Arrow, Rot-2h group); E: rough endoplasmic reticulum,
ribosomes and autophagic vacuoles (Arrow, Rot-6h group); F: mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar
degeneration and autophagic vacuoles (Arrow, Rot-12h group); G: mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar
degeneration and autophagic vacuoles (Arrow, Rot-24h group); H: mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar
degeneration (Arrow, Rot-48h group); I: quantitative analysis of the rate of autophagic vacuoles-containing cells (*P < 0.05, compared
to Con-group).
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hydroxylase (TH) immunoreactivity in the infusion side
by 43.7% four weeks after the infusion [6]. The rotenone
infusion also reduced the DA content, the glutathione
and superoxide dismutase activities, and induced alpha-
synuclein expression, comparing to the contralateral
side. This ST model displayed neither peripheral toxicity
nor mortality, had a high success rate, and recapitulated
the slow and specific loss of DA neurons [6]. Here, the
left and right SNc (from 4.5 to 6.2 mm caudal to the
bregma) of parkinsonian animals were micropunched
and examined by using a TEM. Normal mitochondria,
Golgi complex, ribosomes and medullary sheathes
(Figure 6A), and normal medullary sheathes (Figure 6D)
Figure 6 Rotenone-induced ultrastructural changes in SNc of parkinsonian rats. A: normal mitochondria, Golgi complex and ribosomes in
the contralateral SNc of the parkinsonian animals; B and C: mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar
degeneration, dilated and broken rough endoplasmic reticula, increase in autophagic vacuoles and increase in lysosome density in lesioned SNc
of the parkinsonian animals one or two days after surgery; D: normal medullary sheathes in the contralateral SNc of the parkinsonian animals; E, F
and G: mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar degeneration, dilated and broken rough endoplasmic reticula,
lipofuscin deposition, perinuclear space augmentation and/or increase in autophagic vacuoles in lesioned SNc of the parkinsonian animals one,
two or four weeks after surgery; H: degeneration of the medullary sheathes in lesioned SNc of the parkinsonian animals four weeks after surgery;
I: quantitative analysis of autophagic vacuoles/unit area in SNc neurons (see Table 1 for frequency of occurrence of these ultrastructural changes
at various time points; *P < 0.05, compared to Con-group).
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Normal Mitochondrial
swelling
Mitochondrial
crest fracture
Mitochondrial
vacuolar
degeneration
Dilated and broken
rough endoplasmic
reticula
Lipofuscin
deposition
Perinular space
augmentation
increase of
autophagic
vacuoles/
lysosomes
Degeneration
of medullary
sheathes
Contralateral SNc
(Figure 6A)
Mitochondrial complex
ribosomes, medullary
sheathes
One day after
surgery (Figure
6B)
+++ + +
Two day after
surgery (6C)
++ ++ ++ ++ ++
One week after
surgery (Figure6E)
+++ +++ +++ ++
Two weeks after
surgery (6F)
+++ +++ +++ ++
Four weeks after
surgery (Figure
6G,H)
+++ +++ +++ ++ ++ + ++
Rotenone-administrated animals were sacrificed 1 day, 2 days, 1 week, 2 weeks or 4 weeks after the stereological surgery. A 1-mm3 tissue block from the ipsilateral and contralateral SNc regions (−4.5 to −6.2 mm
caudal to the bregma) was micro-punched for TEM assessment. “+”, frequency of rotenone-induced ultrastructural changes in SNc, including mitochondrial swelling, mitochondrial crest fracture, mitochondrial vacuolar
degeneration, dilated and broken rough endoplasmic reticula, lipofuscin deposition, perinuclear space augmentation and increase in autophagic vacuoles.
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3could be observed in the contralateral SNc of the par-
kinsonian animals. By contrast, there were mitochondrial
swelling, mitochondrial crest fracture, mitochondrial
vacuolar degeneration, dilated and broken rough endo-
plasmic reticula, lipofuscin deposition, perinuclear space
augmentation, degeneration of medullary sheathes, in-
crease in autophagic vacuoles and lysosomes in the le-
sioned SNc of the parkinsonian animals (Figure 6B-C, E-I,
and Table 1).
Discussion
In this study, we have shown that 1) rotenone induces
dose- and time-dependent apoptosis, MMP reduction
and ROS generation in SH-SY5Y; 2) rotenone causes
time- or dose-dependent upregulation of LC3 expression
and decrease in P62 expression in SH-SY5Y; 3) rotenone
induces autophagic vacuole formation in SH-SY5Y cells
and SNc neurons and 4) LC3-positive autophagic vacu-
oles are colocalized with SNCA-overexpressed aggregations.
These data demonstrate the involvement of autophagy in
rotenone-induced parkinsonian models both in vitro and
in vivo.
We suggest that autophagy activation offers neuroprotection
against rotenone-caused parkinsonian. In this study, the
data showed a time-dependent activation of autophagy at
the first 36 hours after rotenone administration and a dra-
matic decrease in autophagy level in these cells 48 hours
after rotenone treatment. Autophagy is an important
cellular response to stress like toxins and oxidative
stress. The accumulation of autophagic vacuoles in the
cytoplasm of SH-SY5Y cells may be attributable to
rotenone-induced toxicity via oxidative stress and
mitochondrial dysfunction. These findings are similar
to the results from previous studies which showing
that oxidative stress may be upstream process of au-
tophagy [44]. The activation of autophagy may help to
prevent cell damage as a compensatory auto-regulative
mechanism. However, when theo v e r l o a do fp a t h o g e n i c
stress exceeds cellular compensation capability, the au-
tophagy may be under the ability to maintain the cellu-
lar balance and ultimately lead to cell death [45]. The
neuroprotective effects of Rap and the neurotoxic ef-
fects of Chl on these models further confirm that the
autophagy enhancement is protective [8].
Previous studies have shown that both autophagy inhib-
ition and enhancement are neuroprotective [7,9,46,47].
The difference may be attributed to different models, dif-
ferent mechanisms involved in these models and different
treatment phases. Increasing evidence demonstrates that
early-stage activation of autophagy is protective and late-
stage over activation of autophagy eventually leads to cell
death. Late-stage neuronal cell loss generally occurs via
autophagy [48]. Abnormal manipulation of autophagy can
result in autophagic cell death or protein-aggregated
neurodegeneration [49-52]. Therefore, precise autophagy
regulation rather than massive autophagy enhancement or
inhibition should be a therapeutic direction of PD.
We suggest that autophagy is a key mechanism involved
in DA cell death rather than an innocent bystander for fol-
lowing reasons. 1) An increase in autophagy-related struc-
tures has been found in parkinsonian patients [53] and
models, suggesting autophagy is involved; 2) pretreatment
of SH-SY5Y cells with the autophagy enhancer Rap is
neuroprotective while pretreatment of SH-SY5Ycells with
the autophagy inhibitor Chl is toxic [8]; and 3) genetically
selective manipulation of autophagy-related genes causes
neurodegeneration and behavioral deficits in animals
[49-51,54].
Conclusions
Autophagy is involved in the pathogenesis of rotenone-
induced PD; autophagy enhancement provides a poten-
tial therapeutic alternative for PD. Moreover, autophagy
is a defense mechanism responsive to rotenone stress for
the DA cell death. Enhancement of autophagy confers
neuroprotection against rotenone toxicity. However,
which autophagy enhancer, such as Rap, lithium, val-
proic acid, carbamazepine or trehalose, would be the
most suitable one for PD patients remains unknown.
Further endeavors are needed to address how to main-
tain proper cellular autophagy level, as well as the safety
issues regarding long-term application of autophagy-
related drugs to PD subjects.
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